Enanta Pharmaceuticals Inc (ENTA) was Downgraded by JMP Securities to ” Mkt Perform”. Earlier the firm had a rating of “Mkt Outperform ” on the company shares. JMP Securities advised their investors in a research report released on Apr 28, 2016.
Many Wall Street Analysts have commented on Enanta Pharmaceuticals Inc. Company shares were Reiterated by Barclays on Feb 9, 2016 to “Underweight”, Firm has raised the Price Target to $ 18 from a previous price target of $16 .
On the company’s financial health, Enanta Pharmaceuticals Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Nov 23, 2015. Analyst had a consensus of $0.24. The company had revenue of $14.40 million for the quarter, compared to analysts expectations of $16.44 million. The company’s revenue was up 453.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Enanta Pharmaceuticals Inc opened for trading at $31.23 and hit $32.08 on the upside on Wednesday, eventually ending the session at $31.81, with a gain of 1.43% or 0.45 points. The heightened volatility saw the trading volume jump to 2,42,114 shares. Company has a market cap of $602 M.
In a different news, on Feb 17, 2016, Terry Vance (director) purchased 2,000 shares at $27.04 per share price. According to the SEC, on Nov 25, 2015, Paul J Mellett (Treasurer and CFO) sold 6,000 shares at $31.23 per share price. On Aug 11, 2015, Yat Sun Or (Chief Scientific Officer) sold 3,750 shares at $42.96 per share price, according to the Form-4 filing with the securities and exchange commission.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.